Zimmer Biomet Deal History & Licensing Activity
Zimmer Biomet is a life sciences. Over the past three years, Zimmer Biomet has been involved in 2 licensing and acquisition transactions, with a primary focus on Other (4 deals). The company currently has 50 active clinical trials, primarily in Autoimmune.
Deals (12mo)
2
Active Trials
50
Top Modality
Other
Focus Area
Autoimmune
Zimmer Biomet Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Zimmer Biomet in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| pain relief system | Pacira Biosciences | Other | Unknown | acquisition | Jul 4, 2026 |
| pain relief system | Pacira | Other | Approved | acquisition | Jun 15, 2026 |
Zimmer Biomet Pipeline Focus
Therapeutic areas and modalities where Zimmer Biomet is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Zimmer Biomet Clinical Pipeline
Zimmer Biomet has 50 active clinical trials across 3 development phases.
32
Unknown
17
Not Applicable
1
Phase 4
See How Your Asset Matches Zimmer Biomet's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Zimmer Biomet Licensing & Deal Activity
Zimmer Biomet is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Zimmer Biomet ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Zimmer Biomet include Autoimmune (10 deals and trials), and Mega Deals (4 deals and trials). In terms of modality, Zimmer Biomet has shown particular interest in other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Zimmer Biomet and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Zimmer Biomet's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.